{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:23:46Z","timestamp":1794435826622,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>L-arginine limits proliferation in highly proliferative tissues. It is a substrate for nitric oxide synthases, arginases; its methylation by protein-L-arginine methyltransferases (PRMTs) leads to asymmetric (ADMA) and symmetric dimethylarginine (SDMA). We measured L-arginine and its metabolites L-ornithine, L-citrulline, ADMA, and SDMA in a prospective cohort of 243 women with primary breast cancer (BC) and their associations with mortality and disease recurrence during 88 (IQR, 82\u201393) months of follow-up. We quantified these metabolites and expression of genes involved in L-arginine metabolic pathways in MCF-7, BT-474, SK-BR-3, MDA-MB-231, and MDA-MB-468 cells representing ER-positive, HER2-positive, and triple-negative BC compared to MCF-12\u00a0A cells. Plasma L-arginine and ADMA concentrations were elevated in 47 patients with recurrent disease and in 34 non-survivors. ADMA was significantly associated with mortality and recurrent disease in Luminal A patients; low L-citrulline was significantly associated with survival in triple-negative BC. In all BC cells except MCF-7, <jats:italic>DDAH1<\/jats:italic> and <jats:italic>DDAH2<\/jats:italic> expression was higher than in MCF-12\u00a0A (<jats:italic>DDAH1<\/jats:italic>: 32\u201344 fold, <jats:italic>DDAH2<\/jats:italic>: 1.7\u20134.2 fold; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). By contrast, MCF-7 cells showed low <jats:italic>DDAH1<\/jats:italic> and <jats:italic>DDAH2<\/jats:italic>, but high <jats:italic>PRMT4<\/jats:italic> and <jats:italic>PRMT6<\/jats:italic> expression and high L-arginine content. BT-474 and MDA-MB-468 cells showed high <jats:italic>ARG2<\/jats:italic> expression and high L-ornithine concentrations, and MDA-MB-468 cells had the highest L-citrulline\/L-arginine ratio. In conclusion, regulation of L-arginine metabolic pathways shows a complex and differential pattern between BC subtypes. ADMA is a prognostic biomarker in Luminal A patients; its metabolizing enzyme, DDAH, is highly overexpressed in BC cells. Thus, fingerprinting of L-arginine metabolism may offer novel personalized treatment options within BC subtypes.<\/jats:p>","DOI":"10.1186\/s12885-025-13908-4","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T17:44:27Z","timestamp":1743011067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["L-arginine dependence of breast cancer \u2013 molecular subtypes matter."],"prefix":"10.1186","volume":"25","author":[{"given":"Juliane","family":"Hannemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Oliveira-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kathrin","family":"Goele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoana","family":"Mileva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Kleinsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"R\u00f6glin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Witzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"B\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"13908_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"13908_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"13908_CR3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186:1708\u201328.","journal-title":"Cell"},{"key":"13908_CR4","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T S\u00f8rlie","year":"2001","unstructured":"S\u00f8rlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13908_CR5","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13908_CR6","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/sj.bjc.6603449","volume":"95","author":"J Hannemann","year":"2006","unstructured":"Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 2006;95:1334\u201341.","journal-title":"Br J Cancer"},{"key":"13908_CR7","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1200\/JCO.2005.09.077","volume":"23","author":"J Hannemann","year":"2005","unstructured":"Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2005;23:3331\u201342.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"13908_CR8","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","volume":"24","author":"A Prat","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, Galv\u00e1n P, Fern\u00e1ndez A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26\u201335.","journal-title":"Breast"},{"key":"13908_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"13908_CR10","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200.","journal-title":"Sci Adv"},{"key":"13908_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168:657\u201369.","journal-title":"Cell"},{"key":"13908_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00726-008-0210-y","volume":"37","author":"G Wu","year":"2009","unstructured":"Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009;37:153\u201368.","journal-title":"Amino Acids"},{"key":"13908_CR13","doi-asserted-by":"crossref","unstructured":"Chen CL, Hsu SC, Ann DK, Yen Y, Kung HJ. Arginine signaling and cancer metabolism. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13143541"},{"key":"13908_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2020.12.041","volume":"502","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chung SF, Tam SY, Leung YC, Guan X. Arginine deprivation as a strategy for cancer therapy: an insight into drug design and drug combination. Cancer Lett. 2021;502:58\u201370.","journal-title":"Cancer Lett"},{"key":"13908_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1042\/cs0820413","volume":"82","author":"KG Park","year":"1992","unstructured":"Park KG, Heys SD, Blessing K, Kelly P, McNurlan MA, Eremin O, et al. Stimulation of human breast cancers by dietary L-arginine. Clin Sci (Lond). 1992;82:413\u20137.","journal-title":"Clin Sci (Lond)"},{"key":"13908_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12885-016-2376-0","volume":"16","author":"Y Cao","year":"2016","unstructured":"Cao Y, Feng Y, Zhang Y, Zhu X, Jin F. L-arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo. BMC Cancer. 2016;16:343.","journal-title":"BMC Cancer"},{"key":"13908_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/his.13334","volume":"72","author":"R El Ansari","year":"2018","unstructured":"El Ansari R, McIntyre A, Craze ML, Ellis IO, Rakha EA, Green AR. Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. 2018;72:183\u201390.","journal-title":"Histopathology"},{"key":"13908_CR18","doi-asserted-by":"crossref","unstructured":"Gandhi N, Das GM. Metabolic reprogramming in breast cancer and its therapeutic implications. Cells. 2019;8.","DOI":"10.3390\/cells8020089"},{"key":"13908_CR19","doi-asserted-by":"publisher","first-page":"835481","DOI":"10.3389\/fmed.2022.835481","volume":"9","author":"J Hannemann","year":"2022","unstructured":"Hannemann J, B\u00f6ger R. Dysregulation of the nitric oxide\/dimethylarginine pathway in hypoxic pulmonary vasoconstriction-molecular mechanisms and clinical significance. Front Med (Lausanne). 2022;9:835481.","journal-title":"Front Med (Lausanne)"},{"key":"13908_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jchromb.2006.11.052","volume":"851","author":"E Schwedhelm","year":"2007","unstructured":"Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, B\u00f6ger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:211\u20139.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"13908_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101\u20138.","journal-title":"Nat Protoc"},{"key":"13908_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32\u20135.","journal-title":"Cancer"},{"key":"13908_CR23","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3945\/jn.111.148197","volume":"141","author":"N L\u00fcneburg","year":"2011","unstructured":"L\u00fcneburg N, Xanthakis V, Schwedhelm E, Sullivan LM, Maas R, Anderssohn M, et al. Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham offspring cohort. J Nutr. 2011;141:2186\u201390.","journal-title":"J Nutr"},{"key":"13908_CR24","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1515\/cclm-2014-0314","volume":"52","author":"D Atzler","year":"2014","unstructured":"Atzler D, Schwedhelm E, Nauck M, Ittermann T, B\u00f6ger RH, Friedrich N. Serum reference intervals of homoarginine, ADMA, and SDMA in the study of health in Pomerania. Clin Chem Lab Med. 2014;52:1835\u201342.","journal-title":"Clin Chem Lab Med"},{"key":"13908_CR25","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1515\/cclm.2011.679","volume":"49","author":"E Schwedhelm","year":"2011","unstructured":"Schwedhelm E, Xanthakis V, Maas R, Sullivan LM, Atzler D, L\u00fcneburg N, et al. Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort. Clin Chem Lab Med. 2011;49:1907\u201310.","journal-title":"Clin Chem Lab Med"},{"key":"13908_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1373\/clinchem.2009.124263","volume":"55","author":"E Schwedhelm","year":"2009","unstructured":"Schwedhelm E, Xanthakis V, Maas R, Sullivan LM, Schulze F, Riederer U, et al. Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort. Clin Chem. 2009;55:1539\u201345.","journal-title":"Clin Chem"},{"key":"13908_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41598-020-80230-3","volume":"11","author":"P Molek","year":"2021","unstructured":"Molek P, Zmudzki P, Wlodarczyk A, Nessler J, Zalewski J. The shifted balance of arginine metabolites in acute myocardial infarction patients and its clinical relevance. Sci Rep. 2021;11:83.","journal-title":"Sci Rep"},{"key":"13908_CR28","doi-asserted-by":"publisher","first-page":"80568","DOI":"10.18632\/oncotarget.19631","volume":"8","author":"P Garrido","year":"2017","unstructured":"Garrido P, Shalaby A, Walsh EM, Keane N, Webber M, Keane MM, et al. Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget. 2017;8:80568\u201388.","journal-title":"Oncotarget"},{"key":"13908_CR29","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1172\/JCI42059","volume":"120","author":"SA Glynn","year":"2010","unstructured":"Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010;120:3843\u201354.","journal-title":"J Clin Invest"},{"key":"13908_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13058-015-0527-x","volume":"17","author":"S Granados-Principal","year":"2015","unstructured":"Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, et al. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res. 2015;17:25.","journal-title":"Breast Cancer Res"},{"key":"13908_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/PL00000852","volume":"58","author":"T Thomas","year":"2001","unstructured":"Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci. 2001;58:244\u201358.","journal-title":"Cell Mol Life Sci"},{"key":"13908_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00726-013-1536-7","volume":"46","author":"TM Weiger","year":"2014","unstructured":"Weiger TM, Hermann A. Cell proliferation, potassium channels, polyamines and their interactions: a mini review. Amino Acids. 2014;46:681\u20138.","journal-title":"Amino Acids"},{"key":"13908_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-014-3156-7","volume":"148","author":"M Cervelli","year":"2014","unstructured":"Cervelli M, Pietropaoli S, Signore F, Amendola R, Mariottini P. Polyamines metabolism and breast cancer: state of the art and perspectives. Breast Cancer Res Treat. 2014;148:233\u201348.","journal-title":"Breast Cancer Res Treat"},{"key":"13908_CR34","doi-asserted-by":"publisher","first-page":"11026","DOI":"10.1158\/0008-5472.CAN-05-1339","volume":"65","author":"X Hu","year":"2005","unstructured":"Hu X, Washington S, Verderame MF, Manni A. Interaction between polyamines and the Mitogen-Activated protein kinase pathway in the regulation of cell cycle variables in breast cancer cells. Cancer Res. 2005;65:11026\u201333.","journal-title":"Cancer Res"},{"key":"13908_CR35","doi-asserted-by":"publisher","first-page":"10063636","DOI":"10.1016\/j.esmoop.2022.100636","volume":"7","author":"A Giannoudis","year":"2022","unstructured":"Giannoudis A, Vareslija D, Sharma V, Zakaria R, Platt-Higgins A, Rudland PS, Jenkinson MD, Young LS, Palmieri C. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO Open. 2022;7:10063636.","journal-title":"ESMO Open"},{"key":"13908_CR36","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.celrep.2019.01.059","volume":"26","author":"I Roci","year":"2019","unstructured":"Roci I, Watrous JD, Lagerborg KA, Lafranchi L, Lindqvist A, Jain M, Nilsson R. Mapping metabolic events in the cancer cell cycle reveals arginine catabolism in the committed SG2M phase. Cell Rep. 2019;26:1691\u2013700.","journal-title":"Cell Rep"},{"key":"13908_CR37","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/bcr2635","volume":"12","author":"A Prat","year":"2010","unstructured":"Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.","journal-title":"Breast Cancer Res"},{"key":"13908_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","volume":"33","author":"MT Bedford","year":"2009","unstructured":"Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell. 2009;33:1\u201313.","journal-title":"Mol Cell"},{"key":"13908_CR39","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41467-023-38467-9","volume":"14","author":"VN Ragavan","year":"2023","unstructured":"Ragavan VN, Nair PC, Jarzebska N, Angom RS, Ruta L, Bianconi E, Grottelli S, Tararova ND, Ryazanskiy D, Lentz SR, Tommasi S, Martens-Lobenhoffer J, Suzuki-Yamamoto T, Kimoto M, Rubets E, Chau S, Chen Y, Hu X, Bernhardt N, Spieth PM, Weiss N, Bornstein SR, Mukhopadhyay D, Bode-B\u00f6ger SM, Maas R, Wang Y, Macchiarulo A, Mangoni AA, Cellini B, Rodionov RN. A multicentric consortium study demonstrates that dimethylarginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolase. Nat Commun. 2023;14:3392.","journal-title":"Nat Commun"},{"key":"13908_CR40","doi-asserted-by":"publisher","first-page":"13996","DOI":"10.1038\/s41598-017-14454-1","volume":"7","author":"JA Hulin","year":"2017","unstructured":"Hulin JA, Tommasi S, Elliot D, Hu DG, Lewis BC, Mangoni AA. MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1. Sci Rep. 2017;7:13996.","journal-title":"Sci Rep"},{"key":"13908_CR41","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1016\/j.molcel.2021.09.011","volume":"81","author":"J Xu","year":"2021","unstructured":"Xu J, Richard S. Cellular pathways influenced by protein arginine methylation: implications for cancer. Mol Cell. 2021;81:4357\u201368.","journal-title":"Mol Cell"},{"key":"13908_CR42","doi-asserted-by":"publisher","first-page":"R223","DOI":"10.1530\/JME-18-0224","volume":"62","author":"SM Wang","year":"2019","unstructured":"Wang SM, Dowhan DH, Muscat GEO. Epigenetic arginine methylation in breast cancer: emerging therapeutic strategies. J Mol Endocrinol. 2019;62:R223\u201337.","journal-title":"J Mol Endocrinol"},{"key":"13908_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12282-017-0790-z","volume":"25","author":"K Nakai","year":"2018","unstructured":"Nakai K, Xia W, Liao HW, Saito M, Hung MC, Yamaguchi H. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer. 2018;25:74\u201380.","journal-title":"Breast Cancer"},{"key":"13908_CR44","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s12276-021-00613-y","volume":"53","author":"JW Hwang","year":"2021","unstructured":"Hwang JW, Cho Y, Bae GU, Kim SN, Kim YK. Protein arginine methyltransferases: promising targets for cancer therapy. Exp Mol Med. 2021;53:788\u2013808.","journal-title":"Exp Mol Med"},{"key":"13908_CR45","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.molonc.2016.09.003","volume":"10","author":"EM Michalak","year":"2016","unstructured":"Michalak EM, Visvader JE. Dysregulation of histone methyltransferases in breast cancer - opportunities for new targeted therapies? Mol Oncol. 2016;10:1497\u2013515.","journal-title":"Mol Oncol"},{"key":"13908_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/mutage\/geu039","volume":"30","author":"A Morettin","year":"2015","unstructured":"Morettin A, Baldwin RM, C\u00f4t\u00e9 J. Arginine methyltransferases as novel therapeutic targets for breast cancer. Mutagenesis. 2015;30:177\u201389.","journal-title":"Mutagenesis"},{"key":"13908_CR47","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1161\/01.CIR.98.18.1842","volume":"98","author":"RH B\u00f6ger","year":"1998","unstructured":"B\u00f6ger RH, Bode-B\u00f6ger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842\u20137.","journal-title":"Circulation"},{"key":"13908_CR48","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/B978-0-12-819460-7.00128-6","volume-title":"Encyclopedia of biological chemistry","author":"J Hannemann","year":"2021","unstructured":"T Hannemann J, B\u00f6ger R. Regulation| t ranscriptional and Post-translational regulation of the dimethylarginines ADMA and SDMA and their impact on the L-arginine \u2013 Nitric oxide pathway. Encyclopedia of biological chemistry. Oxford: Elsevier; 2021. pp. 674\u2013"},{"key":"13908_CR49","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/ATVBAHA.107.156596","volume":"28","author":"T Leong","year":"2008","unstructured":"Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol. 2008;28:961\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"13908_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2017.05.019","volume":"70","author":"BS Finkelman","year":"2017","unstructured":"Finkelman BS, Putt M, Wang T, Wang L, Narayan H, Domchek S, et al. Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer. J Am Coll Cardiol. 2017;70:152\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"13908_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/MCO.0000000000000122","volume":"18","author":"LG Feun","year":"2015","unstructured":"Feun LG, Kuo MT, Savaraj N. Arginine deprivation in cancer therapy. Curr Opin Clin Nutr Metab Care. 2015;18:78\u201382.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"13908_CR52","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1038\/onc.2016.37","volume":"35","author":"MD Patil","year":"2016","unstructured":"Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D. Arginine dependence of tumor cells: targeting a chink in cancer\u2019s armor. Oncogene. 2016;35:4957\u201372.","journal-title":"Oncogene"},{"key":"13908_CR53","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/iub.1581","volume":"68","author":"L Hu","year":"2016","unstructured":"Hu L, Gao Y, Cao Y, Zhang Y, Xu M, Wang Y, et al. Association of plasma arginine with breast cancer molecular subtypes in women of Liaoning Province. IUBMB Life. 2016;68:980\u20134.","journal-title":"IUBMB Life"},{"key":"13908_CR54","doi-asserted-by":"publisher","first-page":"505041","DOI":"10.1155\/2014\/505041","volume":"2014","author":"G Shuvayeva","year":"2014","unstructured":"Shuvayeva G, Bobak Y, Igumentseva N, Titone R, Morani F, Stasyk O, et al. Single amino acid arginine deprivation triggers prosurvival autophagic response in ovarian carcinoma SKOV3. Biomed Res Int. 2014;2014:505041.","journal-title":"Biomed Res Int"},{"key":"13908_CR55","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopha.2018.02.109","volume":"102","author":"M Jahani","year":"2018","unstructured":"Jahani M, Noroznezhad F, Mansouri K, Arginine. Challenges and opportunities of this two-faced molecule in cancer therapy. Biomed Pharmacother. 2018;102:594\u2013601.","journal-title":"Biomed Pharmacother"},{"key":"13908_CR56","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.108.838268","volume":"119","author":"RH B\u00f6ger","year":"2009","unstructured":"B\u00f6ger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592\u2013600.","journal-title":"Circulation"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13908-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13908-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13908-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T08:59:16Z","timestamp":1743325156000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13908-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13908"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13908-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Board of Physicians of Hamburg (OB\/V\/03). All procedures were performed in accordance with the principles of the Declaration of Helsinki. All patients gave their written consent prior to participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"546"}}